

Brandon A Mahal

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/194174/brandon-a-mahal-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

152
papers

2,921
citations

28
h-index

48
g-index

162
ext. papers

4,187
ext. citations

6.5
avg, IF

5.36
L-index

#	Paper	IF	Citations
152	Levels of Evidence for Radiation Therapy Recommendations in the National Comprehensive Cancer Network (NCCN) Clinical Guidelines. <i>Advances in Radiation Oncology</i> , 2022 , 7, 100832	3.3	
151	Racial Differences in Genomic Profiles of Breast Cancer.. <i>JAMA Network Open</i> , 2022 , 5, e220573	10.4	0
150	DNA repair and immune checkpoint blockade response.. <i>Cancer Genetics</i> , 2022 , 264-265, 1-4	2.3	
149	Variation in Molecularly Defined Prostate Tumor Subtypes by Self-identified Race. <i>European Urology Open Science</i> , 2022 , 40, 19-26	0.9	0
148	Reporting of Racial Health Disparities Research: Are We Making Progress?. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101780	2.2	1
147	Prostate Cancer Disparities in Risk Group at Presentation and Access to Treatment for Asian Americans, Native Hawaiians, and Pacific Islanders: A Study With Disaggregated Ethnic Groups. <i>JCO Oncology Practice</i> , 2021 , OP2100412	2.3	1
146	Development and Validation of a Novel TP53 Mutation Signature That Predicts Risk of Metastasis in Primary Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 246-254.e5	3.3	2
145	Psychological Distress and Access to Mental Health Services Among Cancer Survivors: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021 , 36, 3243-3245	4	0
144	Mental Distress and Mental Health Services Receipt in Foreign-Born Survivors of Cancer: a National Health Interview Survey Analysis. <i>Journal of General Internal Medicine</i> , 2021 , 36, 2495-2498	4	0
143	Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis. <i>Lancet Oncology, The</i> , 2021 , 22, 402-410	21.7	21
142	Financial worry and psychological distress among cancer survivors in the United States, 2013-2018. <i>Supportive Care in Cancer</i> , 2021 , 29, 5523-5535	3.9	5
141	Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial. <i>Cancer</i> , 2021 , 127, 2213-2221	6.4	2
140	Factors Influencing Noncompletion of Radiation Therapy Among Men With Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021 , 109, 1279-1285	4	6
139	Racial differences in the treatment and outcomes for prostate cancer in Massachusetts. <i>Cancer</i> , 2021 , 127, 2714-2723	6.4	3
138	Is Medicaid expansion associated with increases in palliative treatments for metastatic cancer?. <i>Journal of Comparative Effectiveness Research</i> , 2021 , 10, 733-741	2.1	0
137	Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences. <i>Communications Biology</i> , 2021 , 4, 670	6.7	18
136	Evolution of Disparities in Prostate Cancer Treatment: Is This a New Normal?. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021 , 41, 1-12	7.1	1

135	Prostate-specific Membrane Antigen and Fluciclovine Transporter Genes are Associated with Variable Clinical Features and Molecular Subtypes of Primary Prostate Cancer. <i>European Urology</i> , 2021 , 79, 717-721	10.2	4
134	Biomarkers in Nonmetastatic Castrate-Resistant Prostate Cancer: A Step in the Right Direction. <i>JAMA Oncology</i> , 2021 , 7, 1014-1015	13.4	
133	Surface applicator high-dose-rate fractionated brachytherapy for superficial cancers of the penis: A single-center case series and national database comparison. <i>Journal of the American Academy of Dermatology</i> , 2021 , 84, 168-172	4.5	0
132	Impact of health literacy on shared decision making for prostate-specific antigen screening in the United States. <i>Cancer</i> , 2021 , 127, 249-256	6.4	3
131	Dose-response with stereotactic body radiotherapy for prostate cancer: A multi-institutional analysis of prostate-specific antigen kinetics and biochemical control. <i>Radiotherapy and Oncology</i> , 2021 , 154, 207-213	5.3	6
130	A Systematic Review of the Evidence for the Decipher Genomic Classifier in Prostate Cancer. <i>European Urology</i> , 2021 , 79, 374-383	10.2	28
129	Health care spending in prostate cancer: An assessment of characteristics and health care utilization of high resource-patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 130.e17-130.e24	2.8	1
128	Association Between Travel Distance and Use of Postoperative Radiation Therapy Among Men With Organ-Confined Prostate Cancer: Does Geography Influence Treatment Decisions?. <i>Practical Radiation Oncology</i> , 2021 , 11, e426-e433	2.8	0
127	Psychological distress and cognition among long-term survivors of adolescent and young adult cancer in the USA. <i>Journal of Cancer Survivorship</i> , 2021 , 15, 776-784	5.1	4
126	Pan-cancer Transcriptomic Predictors of Perineural Invasion Improve Occult Histopathologic Detection. <i>Clinical Cancer Research</i> , 2021 , 27, 2807-2815	12.9	3
125	Disparities in Refusal of Locoregional Treatment for Prostate Adenocarcinoma. <i>JCO Oncology Practice</i> , 2021 , 17, e1489-e1501	2.3	3
124	Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Laboratory Reference Ranges and Testing Intervals Work Group. <i>Clinical Cancer Research</i> , 2021 , 27, 2416-2423	12.9	7
123	Prostate Cancer Racial Disparities: A Systematic Review by the Prostate Cancer Foundation Panel. <i>European Urology Oncology</i> , 2021 ,	6.7	3
122	Clinical characterization of radiation-associated muscle-invasive bladder cancer. <i>Urology</i> , 2021 , 154, 208-214	2.4	1
121	Examining the Racial Disparities in Prostate Cancer. <i>Urology</i> , 2021 ,	1.6	5
120	Prostate tumors of native men from West Africa show biologically distinct pathways-A comparative genomic study. <i>Prostate</i> , 2021 , 81, 1402-1410	4.2	0
119	Novel genomic signature predictive of response to immune checkpoint blockade: A pan-cancer analysis from project Genomics Evidence Neo-plasia Information Exchange (GENIE). <i>Cancer Genetics</i> , 2021 , 258-259, 61-68	2.3	0
118	Looking beyond the Western lens: How culture and identity influence perceptions of empathy in patient-clinician relationships.. <i>Cancer</i> , 2021 ,	6.4	1

117	Comparison of Response to Definitive Radiotherapy for Localized Prostate Cancer in Black and White Men: A Meta-analysis.. <i>JAMA Network Open</i> , 2021 , 4, e2139769	10.4	2
116	Geographic Distribution of Racial Differences in Prostate Cancer Mortality. <i>JAMA Network Open</i> , 2020 , 3, e201839	10.4	17
115	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3024-3031	2.2	11
114	Transcriptomic Heterogeneity of Gleason Grade Group 5 Prostate Cancer. <i>European Urology</i> , 2020 , 78, 327-332	10.2	9
113	Doublecortin Expression in Prostate Adenocarcinoma and Neuroendocrine Tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020 , 108, 936-940	4	1
112	Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer. <i>JAMA Oncology</i> , 2020 , 6, 735-743	13.4	23
111	Inferior Cancer Survival for Men with Localized High-grade Prostate Cancer but Low Prostate-specific Antigen. <i>European Urology</i> , 2020 , 78, 637-639	10.2	3
110	Reply to Obesity and aggressive prostate cancer and the golden rule: Do not do to others what you do not want done to yourself. <i>Cancer</i> , 2020 , 126, 2321-2322	6.4	
109	Validation of a subclassification for high-risk prostate cancer in a prospective cohort. <i>Cancer</i> , 2020 , 126, 2132-2138	6.4	4
108	Performance of clinicopathologic models in men with high risk localized prostate cancer: impact of a 22-gene genomic classifier. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 646-653	6.2	6
107	Outcomes of HPV-Associated Squamous Cell Carcinoma of the Head and Neck: Impact of Race and Socioeconomic Status. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 177-184 ^{7.3}		8
106	General and Health-Related Internet Use Among Cancer Survivors in the United States: A 2013-2018 Cross-Sectional Analysis. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020 , 18, 1468-1475	7.3	7
105	Racial Disparities in Patient-Reported Measures of Physician Cultural Competency Among Cancer Survivors in the United States. <i>JAMA Oncology</i> , 2020 , 6, 152-154	13.4	15
104	Genomic and clinical characterization of stromal infiltration markers in prostate cancer. <i>Cancer</i> , 2020 , 126, 1407-1412	6.4	4
103	Early Impact of the Affordable Care Act and Medicaid Expansion on Racial and Socioeconomic Disparities in Cancer Care. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020 , 43, 163-167 ^{2.7}		10
102	Prostate cancer incidence across stage, NCCN risk groups, and age before and after USPSTF Grade D recommendations against prostate-specific antigen screening in 2012. <i>Cancer</i> , 2020 , 126, 717-724	6.4	36
101	Re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. <i>N Engl J Med</i> 2020;382:2187-96. <i>European Urology</i> , 2020 , 78, e195 ^{10.2}		
100	Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. <i>JAMA Oncology</i> , 2020 , 6, 1912-1920	13.4	15

99	Impact of percent positive biopsy cores on cancer-specific mortality for patients with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 735.e9-735.e15	2.8	1
98	Prostate-specific antigen kinetics and biochemical control following stereotactic body radiation therapy, high dose rate brachytherapy, and low dose rate brachytherapy: A multi-institutional analysis of 3502 patients. <i>Radiotherapy and Oncology</i> , 2020 , 151, 26-32	5.3	11
97	Prostate cancer-specific mortality burden by risk group among men with localized disease: Implications for research and clinical trial priorities. <i>Prostate</i> , 2020 , 80, 1128-1133	4.2	3
96	Relative Timing of Radiotherapy and Androgen Deprivation for Prostate Cancer and Implications for Treatment During the COVID-19 Pandemic. <i>JAMA Oncology</i> , 2020 , 6, 1630-1632	13.4	16
95	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020 , 5, 26-32	3.3	10
94	Racial Differences in Genomic Profiling of Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 1083-1085	59.2	28
93	United States trends in active surveillance or watchful waiting across patient socioeconomic status from 2010 to 2015. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 179-183	6.2	4
92	Prostate Cancer Radiation Therapy Recommendations in Response to COVID-19. <i>Advances in Radiation Oncology</i> , 2020 , 5, 659-665	3.3	100
91	Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC. <i>Oral Oncology</i> , 2019 , 98, 28-34	4.4	6
90	Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores. <i>European Urology</i> , 2019 , 75, 1038-1040	10.2	26
89	Sex Disparity and Copy Number Alterations in Esophageal Squamous Cell Carcinoma. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1207-1209	6.9	1
88	Association of Black Race With Prostate Cancer-Specific and Other-Cause Mortality. <i>JAMA Oncology</i> , 2019 , 5, 975-983	13.4	142
87	Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 104, 778-789	4	127
86	Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer. <i>Cancer</i> , 2019 , 125, 3164-3171	6.4	23
85	Active Surveillance for Low-Risk Prostate Cancer in Black Patients. <i>New England Journal of Medicine</i> , 2019 , 380, 2070-2072	59.2	26
84	Self-reported Reasons and Patterns of Noninsurance Among Cancer Survivors Before and After Implementation of the Affordable Care Act, 2000-2017. <i>JAMA Oncology</i> , 2019 , 5, e191973	13.4	8
83	Racial Disparities in Low-Risk Prostate Cancer-Reply. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 1727-1728	27.4	1
82	Cancer Screening Patterns Among Current, Former, and Never Smokers in the United States, 2010-2015. <i>JAMA Network Open</i> , 2019 , 2, e193759	10.4	18

81	Novel RB1-Loss Transcriptomic Signature Is Associated with Poor Clinical Outcomes across Cancer Types. <i>Clinical Cancer Research</i> , 2019 , 25, 4290-4299	12.9	15
80	Prevalence and Nondisclosure of Complementary and Alternative Medicine Use in Patients With Cancer and Cancer Survivors in the United States. <i>JAMA Oncology</i> , 2019 , 5, 735-737	13.4	20
79	Use of Active Surveillance or Watchful Waiting for Low-Risk Prostate Cancer and Management Trends Across Risk Groups in the United States, 2010-2015. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 321, 704-706	27.4	99
78	Incidence and Demographic Burden of HPV-Associated Oropharyngeal Head and Neck Cancers in the United States. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019 , 28, 1660-1667	4	62
77	Racial disparities in brachytherapy administration and survival in women with locally advanced cervical cancer. <i>Gynecologic Oncology</i> , 2019 , 154, 595-601	4.9	13
76	Conservative management of low-risk prostate cancer among young versus older men in the United States: Trends and outcomes from a novel national database. <i>Cancer</i> , 2019 , 125, 3338-3346	6.4	10
75	Genomic Validation of 3-Tiered Clinical Subclassification of High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 105, 621-627	4	4
74	Mandated health insurance increases rates of elective knee surgery. <i>World Journal of Orthopedics</i> , 2019 , 10, 81-89	2.2	1
73	Comparing the Association Between Insurance and Mortality in Ovarian, Pancreatic, Lung, Colorectal, Prostate, and Breast Cancers. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 1049-1058	7.3	14
72	Practice Patterns and Outcomes Among Patients With N0M0 Prostate Cancer and a Very High Prostate-Specific Antigen Level. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019 , 17, 941-948	7.3	
71	Quality of Care in the Treatment of Localized Intermediate and High Risk Prostate Cancer at Minority Serving Hospitals. <i>Journal of Urology</i> , 2019 , 201, 735-741	2.5	16
70	Combined External Beam Radiation Therapy and Brachytherapy versus Radical Prostatectomy with Adjuvant Radiation Therapy for Gleason 9-10 Prostate Cancer. <i>Journal of Urology</i> , 2019 , 202, 973-978	2.5	17
69	Trends in Smoking and e-Cigarette Use Among US Patients With Cancer, 2014-2017. <i>JAMA Oncology</i> , 2019 , 5, 426-428	13.4	16
68	The Use of e-Cigarettes in Patients With Cancer-A Double Shipwreck-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1372	13.4	1
67	Biology vs Access to Care-Relative Contribution to Racial Disparities in Prostate Cancer-In Reply. <i>JAMA Oncology</i> , 2019 , 5, 1810-1811	13.4	
66	Transcriptomic and Clinical Characterization of Neuropeptide Y Expression in Localized and Metastatic Prostate Cancer: Identification of Novel Prostate Cancer Subtype with Clinical Implications. <i>European Urology Oncology</i> , 2019 , 2, 405-412	6.7	8
65	Patterns of Care and Outcomes of Definitive External Beam Radiotherapy and Radioembolization for Localized Hepatocellular Carcinoma: A Propensity Score-adjusted Analysis. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019 , 42, 564-572	2.7	
64	The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019 , 103, 142-151	4	70

63	Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas. <i>Clinical Cancer Research</i> , 2019 , 25, 2450-2457	12.9	23
62	Impact of tumor, treatment, and access on outcomes in bladder cancer: Can equal access overcome race-based differences in survival?. <i>Cancer</i> , 2019 , 125, 1319-1329	6.4	6
61	A comparative analysis of overall survival between high-dose-rate and low-dose-rate brachytherapy boosts for unfavorable-risk prostate cancer. <i>Brachytherapy</i> , 2019 , 18, 186-191	2.4	12
60	Androgen Deprivation Therapy and Overall Survival for Gleason 8 Versus Gleason 9-10 Prostate Cancer. <i>European Urology</i> , 2019 , 75, 35-41	10.2	12
59	Risk of Upgrading and Upstaging Among 10 000 Patients with Gleason 3+4 Favorable Intermediate-risk Prostate Cancer. <i>European Urology Focus</i> , 2019 , 5, 69-76	5.1	25
58	Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>European Urology</i> , 2018 , 74, 146-154	10.2	50
57	Laboratory Eligibility Criteria as Potential Barriers to Participation by Black Men in Prostate Cancer Clinical Trials. <i>JAMA Oncology</i> , 2018 , 4, 413-414	13.4	8
56	Increased Vulnerability to Poorer Cancer-Specific Outcomes Following Recent Divorce. <i>American Journal of Medicine</i> , 2018 , 131, 517-523	2.4	8
55	Travel Distance as a Barrier to Receipt of Adjuvant Radiation Therapy After Radical Prostatectomy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 953-959	2.7	9
54	Prostate cancer outcomes for men aged younger than 65 years with Medicaid versus private insurance. <i>Cancer</i> , 2018 , 124, 752-759	6.4	17
53	Lack of Apparent Survival Benefit With Use of Androgen Deprivation Therapy in Patients With High-risk Prostate Cancer Receiving Combined External Beam Radiation Therapy and Brachytherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 100, 53-58	4	7
52	Reply to John T. Leppert and James D. Brooks. Letter to the Editor re: Brandon A. Mahal, David D. Yang, Natalie Q. Wang, et al. Clinical and Genomic Characterization of Low-Prostate-specific Antigen, High-grade Prostate Cancer. <i>Eur Urol</i> 2018;74:146-54. <i>European Urology</i> , 2018 , 74, e112-e113	10.2	
51	Safety of combining radiotherapy with immune-checkpoint inhibition. <i>Nature Reviews Clinical Oncology</i> , 2018 , 15, 477-494	19.4	132
50	Travel distance and stereotactic body radiotherapy for localized prostate cancer. <i>Cancer</i> , 2018 , 124, 1146-1149	6.1	14
49	Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 226-234	3.3	12
48	Prostate Cancer-Specific Mortality Across Gleason Scores in Black vs Nonblack Men. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 320, 2479-2481	27.4	68
47	Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. <i>Cancer Cell</i> , 2018 , 34, 549-560.e9	24.3	78
46	HPV status predicts for improved survival following chemotherapy in metastatic squamous cell carcinoma of the oropharynx. <i>Oral Oncology</i> , 2018 , 86, 69-74	4.4	2

45	Early Versus Delayed Initiation of Salvage Androgen Deprivation Therapy and Risk of Prostate Cancer-Specific Mortality. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 727-734	7.3	1
44	Editorial Comment. <i>Journal of Urology</i> , 2017 , 197, 348	2.5	
43	Disparities in the Receipt of Local Treatment of Node-positive Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2017 , 15, 563-569.e3	3.3	7
42	Low rates of androgen deprivation therapy use with salvage radiation therapy in patients with prostate cancer after radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017 , 35, 542.e25-542.e32	2.8	5
41	National Trends and Predictors of Androgen Deprivation Therapy Use in Low-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 98, 338-343	4	8
40	Receipt of definitive therapy in elderly patients with unfavorable-risk prostate cancer. <i>Cancer</i> , 2017 , 123, 4832-4840	6.4	10
39	Risk of prostate cancer mortality in men with a history of prior cancer. <i>BJU International</i> , 2016 , 117, E20-8	8.6	19
38	Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer. <i>Brachytherapy</i> , 2016 , 15, 695-700	2.4	10
37	National sociodemographic disparities in the treatment of high-risk prostate cancer: Do academic cancer centers perform better than community cancer centers?. <i>Cancer</i> , 2016 , 122, 3371-3377	6.4	17
36	Variation in National Use of Long-Term ADT by Disease Aggressiveness Among Men With Unfavorable-Risk Prostate Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016 , 14, 421-8	7.3	9
35	Individual Patient Data Analysis of Randomized Clinical Trials: Impact of Black Race on Castration-resistant Prostate Cancer Outcomes. <i>European Urology Focus</i> , 2016 , 2, 532-539	5.1	13
34	Association Between Treatment at a High-Volume Facility and Improved Survival for Radiation-Treated Men With High-Risk Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016 , 94, 683-90	4	41
33	National trends and determinants of proton therapy use for prostate cancer: A National Cancer Data Base study. <i>Cancer</i> , 2016 , 122, 1505-12	6.4	19
32	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 57.e15-22	2.8	14
31	Health Insurance Affects Head and Neck Cancer Treatment Patterns and Outcomes. <i>Journal of Oral and Maxillofacial Surgery</i> , 2016 , 74, 1241-7	1.8	53
30	Occult High-risk Disease in Clinically Low-risk Prostate Cancer with 50% Positive Biopsy Cores: Should National Guidelines Stop Calling Them Low Risk?. <i>Urology</i> , 2016 , 87, 125-32	1.6	14
29	Gleason score 5 + 3 = 8 prostate cancer: much more like Gleason score 9?. <i>BJU International</i> , 2016 , 118, 95-101	5.6	36
28	Association between very small tumour size and increased cancer-specific mortality after radical prostatectomy in lymph node-positive prostate cancer. <i>BJU International</i> , 2016 , 118, 279-85	5.6	9

27	Asian Americans and prostate cancer: A nationwide population-based analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2016 , 34, 233.e7-15	2.8	24
26	Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1905-12	2.2	92
25	Insurance status and disparities in disease presentation, treatment, and outcomes for men with germ cell tumors. <i>Cancer</i> , 2016 , 122, 3127-3135	6.4	35
24	Association of very low prostate-specific antigen levels with increased cancer-specific death in men with high-grade prostate cancer. <i>Cancer</i> , 2016 , 122, 78-83	6.4	29
23	Differential post-prostatectomy cancer-specific survival of occult T3 vs. clinical T3 prostate cancer: Implications for managing patients upstaged on prostate magnetic resonance imaging. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 330.e19-25	2.8	12
22	Association Between Older Age and Increasing Gleason Score. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, 525-30.e1-3	3.3	13
21	Cancer-specific mortality of Asian Americans diagnosed with cancer: a nationwide population-based assessment. <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv054	9.7	51
20	Marital status and head and neck cancer outcomes. <i>Cancer</i> , 2015 , 121, 1273-8	6.4	95
19	Incidence and Predictors of Upgrading and Up Staging among 10,000 Contemporary Patients with Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2015 , 194, 343-9	2.5	88
18	National trends in the recommendation of radiotherapy after prostatectomy for prostate cancer before and after the reporting of a survival benefit in March 2009. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e167-72	3.3	10
17	Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer. <i>BJU International</i> , 2015 , 116, 358-65	5.6	51
16	Income inequality and treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015 , 33, 18.e7-18.e13	2.8	41
15	Conditional cancer-specific mortality in T4, N1, or M1 prostate cancer: implications for long-term prognosis. <i>Radiation Oncology</i> , 2015 , 10, 155	4.2	12
14	Who bears the greatest burden of aggressive treatment of indolent prostate cancer?. <i>American Journal of Medicine</i> , 2015 , 128, 609-16	2.4	14
13	Shifting brachytherapy monotherapy case mix toward intermediate-risk prostate cancer. <i>Brachytherapy</i> , 2015 , 14, 511-6	2.4	4
12	The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP). <i>Journal of the National Cancer Institute</i> , 2015 , 107, djv261	9.7	35
11	Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e1-6	3.3	15
10	Impact of African-American race on presentation, treatment, and survival of head and neck cancer. <i>Oral Oncology</i> , 2014 , 50, 1177-81	4.4	33

9	Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups. <i>Urology</i> , 2014 , 84, 386-92	1.6	60
8	Racial disparities in prostate cancer-specific mortality in men with low-risk prostate cancer. <i>Clinical Genitourinary Cancer</i> , 2014 , 12, e189-95	3.3	37
7	Hydrogel Spacing for Radiotherapy of Prostate Cancer: A Review of the Literature. <i>Urology Practice</i> , 2014 , 1, 79-85	0.8	7
6	Racial disparities in an aging population: the relationship between age and race in the management of African American men with high-risk prostate cancer. <i>Journal of Geriatric Oncology</i> , 2014 , 5, 352-8	3.6	17
5	Use of a rectal spacer with low-dose-rate brachytherapy for treatment of prostate cancer in previously irradiated patients: Initial experience and short-term results. <i>Brachytherapy</i> , 2014 , 13, 442-9	2.4	27
4	Getting back to equal: The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014 , 32, 1285-91	2.8	62
3	The influence of insurance status on racial disparities in the treatment of African American men with high-risk prostate cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5091-5091	2.2	
2	NGF - the TrkA to successful pain treatment. <i>Journal of Pain Research</i> , 2012 , 5, 279-87	2.9	54
1	The role of phenotyping in chronic prostatitis/chronic pelvic pain syndrome. <i>Current Urology Reports</i> , 2011 , 12, 297-303	2.9	17